West End Peds is proud to have been the first in the DMV area to receive the RSV monoclonal antibody Nirsevimab-Beyfortus!
Nirsevimab-Beyfortus is strongly recommended for all infants under 8 months of age, especially those born during R
SV season or entering their first RSV season.
We’re well-stocked with doses and are meticulously following the recommended administration guidelines for this groundbreaking RSV preventive treatment. We’re thrilled to extend the availability of Beyfortus to all infants who are 8 months and under.
However, through checks, we’ve determined that most insurance carriers won’t cover this treatment for babies older than 8 months. While we earnestly wish all babies could receive this coverage, regrettably, that’s not the current situation.
For those older than 8 months who still wish to receive Beyfortus, we can provide it as an out-of-pocket expense. It is worth noting that the recommendation is to administer Beyfortus for those e infants 0-8 months entering their first RSV season.
Parents who opt for this therapeutic intervention will be required to sign a waiver.
Please don’t hesitate to reach out if you have any further questions or concerns. And reach out to the office to schedule your appt.
We’re here to assist you!
